Agents targeting inflammation in heart failure

Bibliography

• STEWART S, MacINTYRE K,MacLEOD MMC, BAILEY AM, CAPWELL S, McMURRAY JJ: Trends in hospitalization for heart failure in Scotland, 1990-1996. Eur. Heart J. (2001) 22:209–217.
   PubMedGoogle Scholar
• COWIE MR, MOSTERD A, WOOD DA et al.: The epidemiology of heart failure. Eur. Heart J. (1997) 18:208–225.
   PubMed Web of Science ®Google Scholar
• LEVINE B, KALMAN J, MAYER L, FILLIT HM, PACKER M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl. I Med.(1990) 323:236–241.
   PubMed Web of Science ®Google Scholar
• AUKRUST P, UELAND T, LIEN E et al: Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardin]. (1999) 83:376–382.
   PubMed Web of Science ®Google Scholar
• TESTA M, YEH M, LEE P et al: Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J. Am. Coll. Cardin]. (1996) 28:964–971.
   PubMed Web of Science ®Google Scholar
• TORRE-AMIONE G, KAPADIA S, BENEDICT C, ORAL H, YOUNG JB, MANN DL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J. Am. Coll. Cardiol. (1996) 27:1201–1206.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI H, SHIGEMATSU Y, OHTSUKA T: Increased circulating soluble form of Fas in patients with dilated cardiomyopathy. fpn. Circ. J. (1998) 62:873–876.
   PubMed Web of Science ®Google Scholar
• MATSUMORI A, YAMADA T, H, MATOBA Y, SASAYAMA S: levels of cytokines in patients with myocarditis and cardiomyopathy. Br. Heart. (1994) 72:561–566.
   PubMedGoogle Scholar
• SHIOI T, MATSUMORI A, KIHARA Y eta].: Increased expression of interleukin-113 and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ. Res. (1997) 81:644–671.
   Google Scholar
• AUKRUST P, UELAND T, MULLER F et al: Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation (1998) 97:1136–1143.
   PubMed Web of Science ®Google Scholar
• DAMAS JK, GULLESTAD L, T eta].: CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes. Cardiovasc.Res. (2000) 45:428–436.
   Google Scholar
• DAMAS JK, GULLESTAD L, AASS H et al: Enhanced gene expression of chemockines and their corresponding receptors in mononuclear blood cells in chronic heart failure-modulatory effects of intravenous immunoglobulin. ./. Am. Coll. Cardin]. (2001) 38:187–193.
   PubMed Web of Science ®Google Scholar
• DEVEAUX B, SCHOLZ D, HIRCHE A, KLOVERKORN WP, SCHAPER J: Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur. Heart J. (1997) 18:470–479.
   PubMed Web of Science ®Google Scholar
• DAMAS JK, EIKEN HG, OIE E et al: Myocardial expression of CC- and CXC- and their receptors in human-stage heart failure. Cardiovasc. Res. (2000) 47:778–787.
   PubMed Web of Science ®Google Scholar
• KAPADIA S: Cytokines and heart failure.Cardiol Rev (1999) 7:196–206.
   PubMedGoogle Scholar
• SETA Y, SHAN K, BOZKURT B, ORAL H, MANN DL: Basic mechanism in heart failure: the cytokine hypothesis. Cardiac Failure (1996) 2:243–249.
   PubMedGoogle Scholar
• DESWAL A, PETERSEN NJ, FELDMAN AM, YOUNG JB, BG, MANN DL: Cytokines and cytokine receptors in advanced heart failure. Circulation (2001) 103:2055–2059.
   PubMed Web of Science ®Google Scholar
• NATANSON C, EICHENHOLZ PW, DANNER RL et al.: Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J. Exp. Med. (1989) 169(3):823–832.
   PubMed Web of Science ®Google Scholar
• KUBOTA T, McTERNAN CF, FRYE CS et al.: Dilated cardiomyopathy in transgenic mice with cardiac-specific overexspression of tumor necrosis factor-a. Circ. Res. (1997) 81:627–635.
   PubMed Web of Science ®Google Scholar
• BOZKURT B, KRIBBS SB, CLUBB FJ et al.: Pathophysiologically relevant concentrations of tumor necrosis factor-a promote progressive dysfunction and remodelling in rats. Circulation (1998) 97:1382–1391.
   PubMed Web of Science ®Google Scholar
• KUNISADA K, HIROTA H, FUJIO Y et al: Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes. Circulation (1996) 94:2626–2632.
   Google Scholar
• HIROTA H, CHEN J, BETZ AK et al: Loss of gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell (1999) 97:189–198.
   PubMed Web of Science ®Google Scholar
• SASAYAMA S, OKADA M, MATSUMORI A: Chemokines and cardiovascular diseases. Cardiovasc. Res. (2000) 45:267–269.
   PubMed Web of Science ®Google Scholar
• KOLATTUKUDY PE, QUASCH T, BERGES S: Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle. Am. J. Pathol (1998) 152:101–111.
   PubMed Web of Science ®Google Scholar
• COOK DN, BECK MA, COFFMAN TM et al.: Requirement of MIP-1a for an inflammatory response to viral infection. Science (1995) 269:1583–1585.
   PubMed Web of Science ®Google Scholar
• TACHIBANA K, HIROTA S, ILZASA H et al.: The chemokine receptor CXCR4 is essential for vascularization of the tract. Nature (1998) 393:524–525.
   PubMedGoogle Scholar
• NAITO Y, TSUJINO T, FUJIOKA Y, OHYANAGI M, OKAMURA H, IWASAKI T: Increased circulating interleukin-18 in patients with congestive heart failure. Heart (2002) 88(3):296–297.
   PubMed Web of Science ®Google Scholar
• WOLDBAEK PR, TONNESSEN T, HENRIKSEN UL et al.: Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction. Cardiovasc. Res. (203) 59(1):122–131.
   Google Scholar
• YNDESTAD A, UELAND T, OIE E et al: Elevated levels of activin A in heart failure: potential role in myocardial remodeling. Circulation (2004) 109:1379–1385.
   PubMed Web of Science ®Google Scholar
• YNDESTAD A, DAM/86 JK, EIKEN HG et al: Increased gene expression of TNF superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc. Res. (2002) 54:175–182.
   PubMed Web of Science ®Google Scholar
• YNDESTAD A, HOLM AM, MULLER F et al: Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc. Res. (2003) 60:141–146.
   PubMed Web of Science ®Google Scholar
• UELAND T, YNDESTAD A, OIE E et al: Dysregulated osteopotegrin/RANK-ligand/ RANK axis in clinical and experimental heart failure. Circulation (2005) (In Press).
   Google Scholar
• UELAND T, JEMTLAND R, K et al.: Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J. Am. Coll. Cardiol (2004) 44:1970–1976.
   PubMed Web of Science ®Google Scholar
• WALSH MC, CHOI Y: Biology of the TRANCE axis. Cytokine Growth Factor Rev. (2003) 14(3-4):251–263.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO K, SHIOI T, K, MIYAMOTO T, SASAYAMA S, MATSUMORI A: Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-KB activation in knockout mice. J. Am. Coll. Cardiol (2003) 42(11)2000–2006.
   Google Scholar
• GULLESTAD L, AUKRUST P, UELAND T et al.: Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. Am. Coll. Cardiol (1999) 34:2061–2067.
   PubMed Web of Science ®Google Scholar
• SWEDBERG K, HELD P, KJEKSHUS J,RASMUSSEN K, RYDEN L, WEDEL H: Effects of the early administration of on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl. J. Med. (1992) 327:678–684.
   Google Scholar
• MAISEL AS: Beneficial effects of metoprolol treatment in congestive heart failure. Reversal of sympathetic-induced alterations of immunological function. Circulation (1994) 90:1774–1780.
   Google Scholar
• MAISEL AS, MURRAY D, LOTZ M, REARDEN A, IRWIN M, MICHEL MC: Propranolol treatment affects parameters of human immunity. Immunopharmacol (1991) 22:157–164.
   PubMedGoogle Scholar
• HARAGUCHI S, GOOD RA, DAY NK: Immunosuppressive retroviral peptides: cAMP and cytokine patterns. Immunol Today (1995) 16:595–603.
   PubMedGoogle Scholar
• OHTSUKA T, HAMADA M, HIASA G et al.: Effects of B-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol (2001) 37:412–417.
   PubMed Web of Science ®Google Scholar
• GULLESTAD L, UELAND T, BRUNSVIG A et al.: Effect of metoprolol on cytokine levels in chronic heart failure - a substudy in the Metoprolol Controlled-Release Randomized Intervention Trial in Heart failure (MERIT-HF trial). Am. Heart (2001) 141:418–421.
   PubMed Web of Science ®Google Scholar
• TSUTAMOTO T, WADA A, MATSUMOTO T et al: Relationship between tumor necrosis factor-a production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. I Am. Coll. Cardiol (2001) 37:2086–2092.
   PubMed Web of Science ®Google Scholar
• YAMADA T, MATSUMORI A, SASAYAMA S: Therapeutic effect of anti-tumor necrosis factor-a on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation (1994) 89:846–851.
   PubMed Web of Science ®Google Scholar
• DESWAL A, BOZKURT B, SETA Y et al.: Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation (1999) 99:3224–3226.
   PubMed Web of Science ®Google Scholar
• MANN DL, McMURRAY JJ, PACKER M et al.: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 109:1594–1602.
   PubMed Web of Science ®Google Scholar
• LISMAN KA, STETSON SJ, KOERNER T et al: The role of tumor necrosis factor-a in the treatment of congestive heart failure. Congest. Heart Failure (2002) 8:275–279.
   PubMedGoogle Scholar
• KADOKAMI T, McTIERNAN CF, KUBOTA T et al: Effects of soluble TNF receptor treatment on lipopolysaccaride-induced myokardial cytokine expression. Am. J. Physiol (2001) 280:H2281–H2291.
   Web of Science ®Google Scholar
• LUGERING A, SCHMIDT M, LUGERING N, PAUELS HG, DOMSCKE W: Infliximab induces apoptosis in myocytes from patients with chronic active Crohn's disease by using caspase-dependent pathway. Gastroenterology (2001) 121:1145–1157.
   PubMed Web of Science ®Google Scholar
• EVANS TJ, MOYES D, CARPENTER A et al: Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of Gram-negative sepsis. J. Exp. Med. (1994)180(6)2173–2179.
   Google Scholar
• MELDRUM DR: Tumor necrosis factor in the heart. Am. PhysioL (1998) 274:R577–R595.
   PubMed Web of Science ®Google Scholar
• KEITH M, GERANMAYEGAN A, SOLE MJ et al: Increased oxidative stress in patients with congestive heart failure. J. Am. Coll Cardiol (1998) 31:1352–1356.
   PubMed Web of Science ®Google Scholar
• SIN GAL PK, KHAPER N, PALACE V, KUMAR D: The role of oxidative stress in the genesis of heart disease. J. Am. Coll. Cardiovasc.Res. (1998) 40:426–432.
   PubMed Web of Science ®Google Scholar
• KEITH ME, JEEJEEBHOY KN, LANGER A et al.: A controlled trial of vitamin E supplementation in patients with congestive heart failure. Am. J. Clin. Nutr. (2001) 73:219–224.
   PubMed Web of Science ®Google Scholar
• NOLAN Y, MINOGUE A, VEREKER E, BOLTON AE, CAMPBELL VA, LYNCH MA: Attenuation of LPS-induced changes in synaptic activity in rat hippocampus by Vasogen's Immune Modulation Therapy. Neuroimmunomodulation (2002) 10(1):40–46.
   PubMed Web of Science ®Google Scholar
• TORRE-AMI ONEG, SESTIER F, RADOVANCEVIC B, YOUNG J: Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, Phase II J. Am. Coll. Cardiol (2004) 44(6):1181–1186.
   PubMed Web of Science ®Google Scholar
• SLIWA K, SKUDICKY D, CANDY G, WISENBAUGH T, SARELI P: Randomized investigation of effects of on left ventricular performance in idiopathic dilated cardiomyopathy. Lancet (1998) 351:1091–1093.
   PubMed Web of Science ®Google Scholar
• SKUDICKY D, BERGEMANN A, SLIWA K, CANDY G, SARELI P: Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol. Circulation (2001) 103:1083–1088.
   PubMed Web of Science ®Google Scholar
• SLIWA K, WOODIWISS A, KONE VN et al.: Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation (2004) 109(6):750–755.
   PubMed Web of Science ®Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian simvastatin survival study (4S). Lancet (1995) 344:1383–1389.
   Web of Science ®Google Scholar
• THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cgardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of cholesterol levels. N Engl. Med. (1998) 339:1349–1357.
   PubMed Web of Science ®Google Scholar
• KWAK B, MULHAUP F, MYLT S, MACH F: Statins as a newly recognized type of immunomodulator. Nat. Med. (2000) 6:1399–1402.
   PubMed Web of Science ®Google Scholar
• TAKEMOTO M, NODE K, H et al: Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. I Clin. Invest. (2001) 108:1429–1437.
   PubMed Web of Science ®Google Scholar
• KRUM H, McMURRAY JJ: Statins and chronic heart failure: do we need a large scale outcome trial?" Am. Coll. Cardiol (2002) 39:1567–1573.
   PubMed Web of Science ®Google Scholar
• MULLER J, WALLUKAT G, DANDEL M et al.: Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation (2000) 101:285–391.
   Google Scholar
• STAUDT A, SCHAPER F, STANGL V et al.: Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation (2001) 103:2681–2686.
   PubMed Web of Science ®Google Scholar
• NISHIMURA H, OKAZAKI T, TANAKA Y et al: Autoimmune dilated in PD-1 receptor-deficient mice. Science (2001) 291(5502):319–322.
   PubMed Web of Science ®Google Scholar
• OKAZAKI T, TANAKA Y, NISHIO R et al: Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. (2003) 9(12):1477–1483.
   PubMed Web of Science ®Google Scholar
• BALLOW M: Mechanism of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. Allergy Clin. Immunol (1997) 100:151–157.
   Google Scholar
• MOBINI N, SARELA A, AHMED AR: Intravenous immunoglobulins in the therapy of autoimmune and systemic inflammatory disorders. Ann. Allergy Asthma Immunol (1995) 74:119–128.
   PubMed Web of Science ®Google Scholar
• McNAMARA DM, ROSENBLUM WD, JANOSKO KM et al: Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation (1997) 95:2476–2478.
   PubMed Web of Science ®Google Scholar
• BOZKURT B, VILLANEUVA FS, HOLUBKOV R et al: Intravenous immune globulin in the therapy of peripartum cardiomyopathy. I Am. Coll. CardioL (1999) 34:177–180.
   PubMed Web of Science ®Google Scholar
• GULLESTAD L, AASS H, FJELD JG et al.: Effect of immunomodulating therapy with intravenous immunglobulin in chronic congestive heart failure. Circulation (2001) 103:220–225.
   PubMed Web of Science ®Google Scholar
• McNAMARA DM, HOLUBKOV R, STARLING RC et al: Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation (2001) 103:2254–2259.
   PubMed Web of Science ®Google Scholar
• VIARD I, WEHRLI P, SCHNEIDER P et al: Inhibition of toxic necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science (1998) 282:490–493.
   PubMed Web of Science ®Google Scholar
• WOLF HM, EIBL MM: Immunomodulatory effect of immunoglobulins. Clin. Exp. Rheumatol. (1996) 14\(Suppl. 15):517–525.
   Google Scholar
• AUKRUST P, GULLESTAD L, LAPPEGARD KT et al: Complement activation in patients with congestive heart failure-effect of high-dose intravenous immunoglobulin treatment. Circulation (2001) 104:1494–1500.
   PubMed Web of Science ®Google Scholar
• NISHIO R, MATSUMORI A, SHIOI T, ISHIDA H, SASAYAMA S: Treatment of experimental viral myocarditis with interleukin- 10. Circulation (1999) 100:1102–1108.
   PubMed Web of Science ®Google Scholar
• MALLAT Z, BESNARD S, DURIEZ M et al.: Protective role of interleukin-10 in atheroscleosis. Circ. Res. (1999) 85:17–24.
   PubMed Web of Science ®Google Scholar
• LODDICK SA, ROTHWELL NJ: Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. I Cereb. Blood Flow. Metab. (1996) 16:932–940.
   PubMed Web of Science ®Google Scholar
• UNGUREANU-LONGROIS D, BALLIGAND J-L, SIMMONS WW et al: Induction of nitric oxide synthase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease contractile responsivness to 0-adrenergic agonists. Circ. Res. (1995) 77:494–502.
   PubMed Web of Science ®Google Scholar
• JACOBSEN JM: Thalidomide: a remarkable comeback. Expert Opin. Pharmacother. (2000) 1:849–863.
   PubMedGoogle Scholar
• ADLARD JW: Thalidomide in the treatment of cancer. Anticancer Drugs (2000) 11:787–791.
   PubMed Web of Science ®Google Scholar
• SAMPAIO EP, SARNO EN, GALILLY R, COHN ZA, KAPLAN G: Thalidomide selectively inhibits tumor necrosis factor-a production by stimulated human monocytes. J. Exp. Med. (1991) 173:699–703.
   PubMed Web of Science ®Google Scholar
• CORRAL LG, HASLETT PA, GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a.. (1999) 163:380–386.
   Google Scholar
• KEIFER JA, GUTTRIDGE DC, ASHBURNER AP, BALDWIN J: Inhibition of NF-KB activity by thalidomide throuh suppression of I KB kinase activity. ./. Biol. Chem. (2001) 267:22382–22387.
   Google Scholar
• ZORAT F, SHETTY V, DUTT D et al.:The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br. I Haematol. (2001) 115:881–894.
   PubMed Web of Science ®Google Scholar
• BARLETT JB, MICHAEL A, CLARKE IA et al: Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer (2004) 90:955–961.
   PubMed Web of Science ®Google Scholar
• GELATI M, CORSINI E, FRIGERIO S et al.: Effects of thalidomide on parameters involved in angiogenesis: an in vitro study. Neurooncol. (2003) 64:193–201.
   PubMed Web of Science ®Google Scholar
• ASAKAWA M, TAKANO H, NAGAI T et al.: Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation (2002) 105(10):1240–1246.
   PubMed Web of Science ®Google Scholar
• TIEDEMANN H, ASASHIMA M, GRUNZ H, KNOCHEL W: Pluripotent cells (stem cells) and their determination and differentiation in early vertebrate embryogenesis. Devel. Growth Diff. (2001) 43(5):469–502.
   PubMed Web of Science ®Google Scholar
• LIMAS CJ, HASIKIDIS C, IAKOVOU J, KROUPIS C, HAIDAROGLOU A, COKKINOS DV: Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Eur.. (2003) 33(6):443–448.
   Google Scholar
• GREEN JM: The B7/CD28/CTLA4 T-cell activation pathway. Implications for inflammatory lung disease. Am. j Resp. Cell Mol. Biol. (2000) 22(3):261–264.
   PubMed Web of Science ®Google Scholar
• SALOMON B, BLUESTONE JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. AMU. Rev Immunol. (1919):225–252.
   Google Scholar
• KREMER JM, WESTHOVENS R, LEON M et al: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4-Ig. N. Engl. J. Med. (2003) 349(20):1907–1915.
   PubMed Web of Science ®Google Scholar
• HAYASHIDANI S, TSUTSUI H, SHIOMI T et al.: Anti-monocyte protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation (2003) 108(17):2134–2140.
   PubMed Web of Science ®Google Scholar
• SUZUKI K, MURTUZA B, RT et al.: Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. Circulation (2001)104(12 Suppl. 1):1308–1313.
   Google Scholar
• TAKANO H, NAGAI T, ASAKAWA M et al.: Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ. Res. (2000) 87(7):596–602.
   PubMed Web of Science ®Google Scholar
• HARA M, ONO K, HWANG MW et al.:Evidence for a role of mast cells in the evolution to congestive heart failure. J. Exp. Med. (2002) 195:375–381.
   PubMed Web of Science ®Google Scholar
• HOCHER B, GODES M, OLIVIER J et al.: Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. J. Hypertension (2002) 20(4):745–751.
   PubMed Web of Science ®Google Scholar